Stocks News

LAST PRICE
53.7800
TODAY'S CHANGE (%)
Trending Down-1.6200 (-2.9242%)

Bid / Lots
53.4100/ 1
Ask / Lots
54.2300/ 1
Open / Previous Close
55.6700 / 55.4000
Day Range
Low 52.7400
High 55.6700
52 Week Range
Low 20.9600
High 62.5800
Volume
926,800
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 5, 2024
- Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition, from 9:05AM ET on Tuesday Nov 05, 2024 by Dow Jones
  9:05AM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: AGIO
  
  whether as a result of new information, future events or otherwise, except as required by law.
  
  Contacts:
  
  Investor Contact
  
  Chris Taylor, VP, Investor Relations and Corporate Communications
Nov 1, 2024
- DJ Agios Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 12:43PM ET on Friday Nov 01, 2024 by Dow Jones
  12:43PM ET on Friday Nov 01, 2024 by Dow Jones
  Companies Mentioned: AGIO
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/AGIO/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 01, 2024 12:43 ET (16:43 GMT)
- DJ Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank, from 10:30AM ET on Friday Nov 01, 2024 by Dow Jones
  10:30AM ET on Friday Nov 01, 2024 by Dow Jones
  Companies Mentioned: AGIO
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/AGIO/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 01, 2024 10:30 ET (14:30 GMT)
Oct 31, 2024
- Agios Pharmaceuticals Shares Fall After Q3 Revenue Miss, from 10:34AM ET on Thursday Oct 31, 2024 by MT Newswires
  10:34AM ET on Thursday Oct 31, 2024 by MT Newswires
  Companies Mentioned: AGIO
  10:34 AM EDT, 10/31/2024 (MT Newswires) -- Agios Pharmaceuticals (AGIO) shares fell 2.7% in recent Thursday trading after the company's Q3 revenue fell below market expectations. The biopharmaceutical company reported Q3 net income Thursday of $16.2...
- -- Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Reports Q3 Revenue $9.0M, from 6:30AM ET on Thursday Oct 31, 2024 by MT Newswires
  6:30AM ET on Thursday Oct 31, 2024 by MT Newswires
  Companies Mentioned: AGIO
  06:30 AM EDT, 10/31/2024 (MT Newswires) -- ...

Nov 14, 2024
- Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 8:00AM ET on Thursday Nov 14, 2024 by PR Newswire
  8:00AM ET on Thursday Nov 14, 2024 by PR Newswire
  Companies Mentioned: IOVA, ONCY, SWTX, IBRX, SNDX
- Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 8:00AM ET on Thursday Nov 14, 2024 by CNW Group
  8:00AM ET on Thursday Nov 14, 2024 by CNW Group
  Companies Mentioned: IOVA, ONCY, SWTX, IBRX, SNDX
- DJ MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co., from 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: MLTX
Nov 13, 2024
- Xenon to Present at Upcoming Investor Conferences, from 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
  4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: XENE
- DJ Xenon Pharmaceuticals Price Target Maintained With a $53.00/Share by HC Wainwright & Co., from 11:48AM ET on Wednesday Nov 13, 2024 by Dow Jones
  11:48AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: XENE
- MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody(R) sonelokimab in patients with active psoriatic arthritis, from 8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
  8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: MLTX
- DJ Xenon Pharmaceuticals Price Target Maintained With a $60.00/Share by Needham, from 6:44AM ET on Wednesday Nov 13, 2024 by Dow Jones
  6:44AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: XENE
Nov 12, 2024
- Xenon Pharmaceuticals Q3 Net Loss Widens, from 4:19PM ET on Tuesday Nov 12, 2024 by MT Newswires
  4:19PM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: XENE
- Xenon Reports Q3 2024 Financial Results and Business Update, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
  4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: XENE
- *DJ Xenon Pharmaceuticals 3Q Loss/Shr 81c >XENE, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
  4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: XENE

Agios Pharmaceuticals Inc
NASDAQ:AGIOUnited States

Search Criteria

Nov 5, 2024

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition, from 9:05AM ET on Tuesday Nov 05, 2024 by Dow Jones

Nov 1, 2024

DJ Agios Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 12:43PM ET on Friday Nov 01, 2024 by Dow Jones

DJ Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank, from 10:30AM ET on Friday Nov 01, 2024 by Dow Jones

Oct 31, 2024

Agios Pharmaceuticals Shares Fall After Q3 Revenue Miss, from 10:34AM ET on Thursday Oct 31, 2024 by MT Newswires

-- Earnings Flash (AGIO) AGIOS PHARMACEUTICALS Reports Q3 Revenue $9.0M, from 6:30AM ET on Thursday Oct 31, 2024 by MT Newswires

Peers Headlines

Nov 14, 2024

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 8:00AM ET on Thursday Nov 14, 2024 by PR Newswire

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 8:00AM ET on Thursday Nov 14, 2024 by CNW Group

DJ MoonLake Immunotherap Price Target Maintained With a $100.00/Share by HC Wainwright & Co., from 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 13, 2024

Xenon to Present at Upcoming Investor Conferences, from 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones

DJ Xenon Pharmaceuticals Price Target Maintained With a $53.00/Share by HC Wainwright & Co., from 11:48AM ET on Wednesday Nov 13, 2024 by Dow Jones

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody(R) sonelokimab in patients with active psoriatic arthritis, from 8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones

DJ Xenon Pharmaceuticals Price Target Maintained With a $60.00/Share by Needham, from 6:44AM ET on Wednesday Nov 13, 2024 by Dow Jones

Nov 12, 2024

Xenon Pharmaceuticals Q3 Net Loss Widens, from 4:19PM ET on Tuesday Nov 12, 2024 by MT Newswires

Xenon Reports Q3 2024 Financial Results and Business Update, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones

*DJ Xenon Pharmaceuticals 3Q Loss/Shr 81c >XENE, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones